NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the topic.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Guckerman, MD, and Naval G. Daver, MD, also contribute to the discussion.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Additional experts like Anne Chiang, MD, PhD, and J. Douglas Miles, MD, PhD, FAAN, provide further perspectives on the benefits of NGS in solid tumor treatment.
Author's summary: NGS enhances biomarker testing for solid tumors.
More News
- Mountain View council member talks climate policy with Saint Francis students
- Lions Club and County Commission unveil plaque celebrating Fayette County’s NBA Greats - WOAY-TV
- Road reconstruction near Maxville nearly complete
- Lions donate $105,000 to Maxville Manor redevelopment
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Molecular Processing Archives - Talk Business & Politics
- ChatGPT ‘surprisingly accurate’ at giving car repair advice, study finds
- UAMS receives $4 million to reduce maternal mortality in Ashley and Union counties - Talk Business & Politics